Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Goes Academic: Pharma Will Be Led By Harvard Med's Leiden

Executive Summary

Abbott is casting aside its traditional formula for senior drug management and turning its pharmaceutical division over to the recently recruited head of research, Jeffrey Leiden, MD/PhD.
Advertisement

Related Content

Abbott COO Succession: Leiden Leaves, Gonzalez Takes Over Pharma Group
Abbott COO Succession: Leiden Leaves, Gonzalez Takes Over Pharma Group
Abbott Rx For R&D Includes Tandem Drug/Biologic Development
Abbott Rx For R&D Includes Tandem Drug/Biologic Development
Pfizer R&D Changes: Corr Succeeds Niblack, R&D Integrated With Marketing
Abbott Compound Library Near 1 Mil., Company Tells Analysts At R&D Day
Abbott Compound Library Near 1 Mil., Company Tells Analysts At R&D Day
Abbott U.S. Pharma Head Is Goffredo: Higgins Becomes Enzon CEO
TAP Uprima 3 Mg Dose Studies To Be Completed This Summer; NDA Withdrawn
TAP Uprima 3 Mg Dose Studies To Be Completed This Summer; NDA Withdrawn
Advertisement
UsernamePublicRestriction

Register

PS036398

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel